Proportion of patients with systemic inflammation and their characteristics for groups at high cardiovascular risk in phase 3 randomized placebo-controlled trials of semaglutide (SELECT, SOUL, FLOW)

28 August 2023 (16:10 - 16:20)
Organised by: Logo
Congress Presentation Part of: The heart and the kidney Renal Failure and Cardiovascular Disease ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology